Open AccessA Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
Author(s) -
Qingli Cui,
Yanhui Hu,
Dongyang Ma,
Huaimin Liu
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s286529
Subject(s) - platinum , refractory (planetary science) , medicine , observational study , oncology , retrospective cohort study , ovarian cancer , cancer , biology , materials science , metallurgy , biochemistry , catalysis
Anlotinib, an oral small-molecular tyrosine kinase inhibitor (TKI) on tumor angiogenesis and growth, has a wide spectrum of inhibitory effects on targets such as vascular endothelial growth factor receptors 2/3 (VEGFR2/3), etc. The efficacy and safety of anlotinib in the treatment of platinum-resistant or platinum-refractory ovarian cancer were evaluated.